Scolaris Content Display Scolaris Content Display

Cochrane Database of Systematic Reviews

Artesunate versus quinine for treating severe malaria

This is not the most recent version

Information

DOI:
https://doi.org/10.1002/14651858.CD005967.pub2Copy DOI
Database:
  1. Cochrane Database of Systematic Reviews
Version published:
  1. 17 October 2007see what's new
Type:
  1. Intervention
Stage:
  1. Review
Cochrane Editorial Group:
  1. Cochrane Infectious Diseases Group

Copyright:
  1. Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Article metrics

Altmetric:

Cited by:

Cited 0 times via Crossref Cited-by Linking

Collapse

Authors

  • Katharine L Jones

    International Health Group, Liverpool School of Tropical Medicine, Liverpool, UK

  • Sarah Donegan

    Correspondence to: International Health Group, Liverpool School of Tropical Medicine, Liverpool, UK

    [email protected]

  • David G Lalloo

    Clinical Research Group, Liverpool School of Tropical Medicine, Liverpool, UK

Contributions of authors

Katharine Jones and Sarah Donegan assessed the eligibility and methodological quality of trials, extracted and analysed data, and drafted the review. David Lalloo contributed to the design and writing of the review.

Sources of support

Internal sources

  • Liverpool School of Tropical Medicine, UK.

  • University of Liverpool, UK.

External sources

  • Department for International Development (DFID), UK.

Declarations of interest

Dr David Lalloo was part of the data and safety monitoring committee for the Dondorp trial. This committee is independent, does not run or gain anything from the trial, and has a main role of protecting participants.

Acknowledgements

Advice and support were provided by Prof Paul Garner, Manager of the Effective Health Care Research Programme Consortium (Effective Health Care RPC) at the Liverpool School of Tropical Medicine. This protocol was developed during a contract with the Effective Health Care RPC, which is funded by the UK Department for International Development (DFID).

This document is an output from a project funded by the DFID for the benefit of developing countries. The views expressed are not necessarily those of DFID.

Version history

Published

Title

Stage

Authors

Version

2012 Jun 13

Artesunate versus quinine for treating severe malaria

Review

David Sinclair, Sarah Donegan, Rachel Isba, David G Lalloo

https://doi.org/10.1002/14651858.CD005967.pub4

2011 Mar 16

Artesunate versus quinine for treating severe malaria

Review

David Sinclair, Sarah Donegan, David G Lalloo

https://doi.org/10.1002/14651858.CD005967.pub3

2007 Oct 17

Artesunate versus quinine for treating severe malaria

Review

Katharine L Jones, Sarah Donegan, David G Lalloo

https://doi.org/10.1002/14651858.CD005967.pub2

2006 Apr 19

Artesunate versus quinine for treating severe malaria

Protocol

Katharine L Jones, Sarah Donegan, David Lalloo

https://doi.org/10.1002/14651858.CD005967

Differences between protocol and review

2007, Issue 4 (first review version): We removed the requirement for all participants to fulfil the World Health Organization's definition for severe malaria (Gilles 2000) in view of the large number of participants this would have excluded from the review as the largest included trial used a clinical case definition. We changed the intervention from "parenteral quinine" to "intravenous, intramuscular, or rectal artesunate" to clarify that trials using artesunate suppositories were included in the review. We changed "neurological sequelae" to "neurological sequelae at discharge" to clarify the follow‐up period for this outcome. We added the exploration of a number of post‐hoc sources of heterogeneity for mortality after noting significant variation in study design across trials. We presented data for hypoglycaemia in a forest plot rather than a table as stated in the protocol to reflect the clinical importance of this outcome.